Literature DB >> 1730616

Assembly and aggregation properties of synthetic Alzheimer's A4/beta amyloid peptide analogs.

D Burdick1, B Soreghan, M Kwon, J Kosmoski, M Knauer, A Henschen, J Yates, C Cotman, C Glabe.   

Abstract

The amyloid A4 or beta peptide is a major component of extracellular amyloid deposits that are a characteristic feature of Alzheimer's disease. We synthesized a series of peptide analogs of the A4/beta peptide which are progressively longer at their carboxyl termini, including 42- and 39-residue peptides which represent the major forms of the A4/beta peptide in senile plaque and the hereditary cerebral hemorrhage with amyloidosis form, respectively. All peptides tested, beta 1-28 through beta 1-42, formed amyloid-like fibrils and previously unreported thin sheet-like structures which stained with thioflavin T and Congo Red. The solubility of beta 1-42 and shorter peptides was pH and concentration dependent, with a broad insolubility profile in the pH range of 3.5-6.5 and at concentrations above 0.75 mg/ml. Only peptides of 42 residues or longer were significantly insoluble at pH 7.4. beta 1-47 and beta 1-52 peptides are highly insoluble in aqueous media but are soluble at 40 mg/ml in the alpha helix-promoting solvent, 1,1,1,3,3,3-hexafluoro-2-propanol. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis revealed that the beta 1-42 peptide migrates as a series of higher molecular mass aggregates whereas shorter peptides migrate as monomers. Aggregation is also dependent on pH, peptide concentration, and time of incubation in aqueous medium. These results indicate that the length of the hydrophobic carboxyl terminus of the A4/beta peptide is important in determining the solubility and aggregation properties of the A4/beta peptide and that acid pH environment, high peptide concentration, and long incubation time would be predicted to be important factors in promoting amyloid deposition.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1730616

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  213 in total

1.  Alzheimer's beta-amyloid peptides can activate the early components of complement classical pathway in a C1q-independent manner.

Authors:  L Bergamaschini; S Canziani; B Bottasso; M Cugno; P Braidotti; A Agostoni
Journal:  Clin Exp Immunol       Date:  1999-03       Impact factor: 4.330

2.  A cell surface receptor complex for fibrillar beta-amyloid mediates microglial activation.

Authors:  Maria E Bamberger; Meera E Harris; Douglas R McDonald; Jens Husemann; Gary E Landreth
Journal:  J Neurosci       Date:  2003-04-01       Impact factor: 6.167

3.  Inhibitors of amyloid toxicity based on beta-sheet packing of Abeta40 and Abeta42.

Authors:  Takeshi Sato; Pascal Kienlen-Campard; Mahiuddin Ahmed; Wei Liu; Huilin Li; James I Elliott; Saburo Aimoto; Stefan N Constantinescu; Jean-Noel Octave; Steven O Smith
Journal:  Biochemistry       Date:  2006-05-02       Impact factor: 3.162

4.  Structure of A beta(25-35) peptide in different environments.

Authors:  Ganesh Shanmugam; Prasad L Polavarapu
Journal:  Biophys J       Date:  2004-07       Impact factor: 4.033

5.  Beta-amyloid peptide at sublethal concentrations downregulates brain-derived neurotrophic factor functions in cultured cortical neurons.

Authors:  Liqi Tong; Robert Balazs; Phillip L Thornton; Carl W Cotman
Journal:  J Neurosci       Date:  2004-07-28       Impact factor: 6.167

Review 6.  Current therapeutic targets for the treatment of Alzheimer's disease.

Authors:  Joshua D Grill; Jeffrey L Cummings
Journal:  Expert Rev Neurother       Date:  2010-05       Impact factor: 4.618

7.  Tautomeric Effect of Histidine on β-Sheet Formation of Amyloid Beta 1-40: 2D-IR Simulations.

Authors:  Yeonsig Nam; Mahroof Kalathingal; Shinji Saito; Jin Yong Lee
Journal:  Biophys J       Date:  2020-07-18       Impact factor: 4.033

Review 8.  Transgenic mouse models of neurodegenerative disease: opportunities for therapeutic development.

Authors:  Joanna L Jankowsky; Alena Savonenko; Gabriele Schilling; Jiou Wang; Guilian Xu; David R Borchelt
Journal:  Curr Neurol Neurosci Rep       Date:  2002-09       Impact factor: 5.081

9.  Arginine and disordered amyloid-β peptide structures: molecular level insights into the toxicity in Alzheimer's disease.

Authors:  Orkid Coskuner; Olivia Wise-Scira
Journal:  ACS Chem Neurosci       Date:  2013-10-08       Impact factor: 4.418

Review 10.  Antibody-Based Drugs and Approaches Against Amyloid-β Species for Alzheimer's Disease Immunotherapy.

Authors:  Jing Liu; Bin Yang; Jun Ke; Wenjia Li; Wen-Chen Suen
Journal:  Drugs Aging       Date:  2016-10       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.